Company on track to submit NDA to U.S. FDA for avasopasem by end of 2022
Phase 3 ROMAN trial data highlighted in an oral presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
Read more at globenewswire.comAll information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
Company on track to submit NDA to U.S. FDA for avasopasem by end of 2022
Phase 3 ROMAN trial data highlighted in an oral presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
Read more at globenewswire.com| Symbol | Last | Chg | %Chg |
|---|---|---|---|
| GRTX | 0.0225 | -0.0003 | -1.32% |
| Galera Therapeutics Inc | |||